Image via Endpoints News
Last updated
Amgen: Ma Activity
Amgen is terminating its partnership with TScan Therapeutics, a T cell therapy company based in Waltham, MA.
Source: Endpoints News
The leadership read
Consolidation shifts the leadership question from growth to integration. For Amgen in Biotech & Pharma, the demand moves toward transformation and integration leaders who can merge teams, systems and cultures without losing momentum. Across Americas, watch whether the integration is properly resourced; deals are won or lost the year after they close.
Market context: Against a Talent Market Index of 100.1 (Neutral) (down 1.1 month-on-month), Americas is at easing (-1.8pts) on signal share.
Amgen: 4 signals in the last 90 days — above the Biotech & Pharma median of 1.5 across 24 tracked companies; 0.2% of MitchelLake's EMEA signal flow; 4 tracked across 79 days.
MitchelLake in this thematic
Also at Amgen →
More signals across Biotech & Pharma
Ma Activity · Americas
Biogen →Biogen completed acquisition of RayThera Inc., with the acquired company's lead program now in Phase 1 development.
Ma Activity · Americas
Teva Pharmaceuticals →Federal judge approved $35M settlement with healthcare funds over allegations Teva delayed generic versions of asthma inhalers, causing higher prices
Ma Activity · Americas
Bristol Myers Squibb →Bristol Myers Squibb is in merger talks with AstraZeneca regarding a potential $400 billion megadeal
Ma Activity · Americas
Gilead Sciences →Gilead Sciences acquires Tubulis GmbH for $3.15B to expand oncology portfolio
Ma Activity · Americas
Bora Pharmaceuticals →Bora Group announced acquisition of MacroGenics' GMP manufacturing operations and CDMO business for US$122.5 million plus up to US$5 million contingent consideration. Includes biologics manufacturing facility in Rockville, Maryland with substantial backlog.
Capital Raising · Americas
Twist Bioscience →Twist Bioscience completed a US$300 million follow-on equity offering at US$96/share, upsized from an initially filed US$250 million raise. Concurrent with Q3 2026 results showing US$118.38M revenue and US$35.05M loss, company raised FY2026 guidance to US$456-457M.
Where this lands in our work
- Private Equity →
Ownership change resets the executive requirement — value-creation leadership follows the deal.
- Executive Search — Americas →
Our Americas practice runs the searches behind signals like this one.
Intelligence powered by Autonodal ↗
Nearby in the record